All In Biotech

NDA 018931 · Baxter Hlthcare

Travasol 10% In Plastic Container

Amino Acids · Injection · Amino Acid

Last checked: Nov 21, 2026Latest source record: Sep 23, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

Aug 23, 1984

Approved uses

1

Original approval plus efficacy supplements

Registered trials

30,329

6,604 Phase 3, 2,683 recruiting

FAERS reports

66

42 serious, 9 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 7, 2020.

TRAVASOL is indicated as a source of amino acids for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. TRAVASOL may be used to treat negative nitrogen balance in patients. TRAVASOL is indicated as a source of amino acids for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. TRAVASOL may be used to treat negative nitrogen balance in patients. (1)

Mechanism: TRAVASOL is used as a supplement of nutrition in patients, providing amino acids parenterally. The amino acids provide the structural units that make up proteins and are used to synthesize proteins and other biomolecules or are oxidized to urea and carbon dioxide as a source of energy.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 23, 1984 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
  • TRAVASOL 10% IN PLASTIC CONTAINER · AMINO ACIDS 10% (10MG/100ML) · INJECTABLE, INJECTION · Prescription
  • TRAVASOL 5.5% IN PLASTIC CONTAINER · AMINO ACIDS 5.5% (5.5GM/100ML) · INJECTABLE, INJECTION · Prescription
  • TRAVASOL 8.5% IN PLASTIC CONTAINER · AMINO ACIDS 8.5% (8.5GM/100ML) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Amino Acids" as an intervention, any sponsor and status, largest first.

All 30,329 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • no adverse event9
  • vomiting7
  • death6
  • incorrect dose administered6
  • dyspnoea5
  • pain5
  • fatigue4
  • nausea4
  • transfusion4
  • blood fibrinogen increased3
  • blood glucose decreased3
  • drug dispensing error3

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20054
20134
20143
20159
20164
20175
20185
20196
20206
20214
20224
20232
20245
20252
20263

Recalls

1 FDA enforcement reports for this application.

  • Nov 12, 2013 · Class II · Terminated

    Lack of Assurance of Sterility; Drug product leaking from container therefore sterility cannot be assured

Shortages

FDA's drug shortage list.

  • Current · updated Nov 18, 2026

    Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40...

  • Current · updated Nov 18, 2026

    Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40...

  • Current · updated Nov 18, 2026

    Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40...

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,553 on PubMed

Sponsor: Baxter Hlthcare · Also marketed as Travasol 5.5% In Plastic Container, Travasol 8.5% In Plastic Container

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.